ANTHEM Anthem Biosciences Q2 FY26 results (Jul–Sep 2025) and concall
Anthem Biosciences reported a strong H1 FY26 with consolidated revenue of ₹1,090 crores, EBITDA of ₹480 crores (41.4% margin), and PAT of ₹309 crores (26.6% margin). The company expanded its commercial portfolio to 14 molecules and commissioned new capacities in Unit-II. While specialty ingredients saw a temporary decline, management expressed confidence in overall growth and the long-term potential of new capacities and pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 5.1%, net profit up 16.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 525 | 498 | 479 | 538 | 552 +5% |
| EBITDA | 201 | 167 | 198 | 195 | 226 +12% |
| Net profit | 170 | 128 | 123 | 148 | 198 +16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
